Introduction {#S1}
============

Toll-like receptors (TLRs) are a family of pattern recognition receptors distinguished by their role of phylaxis. TLRs recognize pathogen-associated molecular patterns (PAMPs) and activate immune signaling through innate and acquired immunity ([@B1]--[@B3]). Particularly, TLR4 recognizes lipopolysaccharide (LPS) derived from gram-negative bacteria and induces production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, interferon (IFN)-γ, and IL-12 from macrophages and dendritic cells. However, excessive cytokine production results in a "cytokine storm," which can induce lethal endotoxin shock ([@B4], [@B5]). TLR9 acts as a first-line host defense against pathogens recognizing DNA comprising unmethylated CpG motifs present in bacteria and viruses ([@B6]). Nucleic acid therapeutics including oligodeoxynucleotides (ODNs) from bacterial genomic DNA and microRNA are potential targeted therapies as they can strongly regulate gene expression and immune response ([@B7]--[@B10]). CpG motifs are at least 20-fold more common in bacterial DNA compared with vertebrate DNA and act as a PAMP ([@B2]). Mammalian TLR9 directly binds to unmethylated CpG DNA (CpG ODN) in the endolysosome/lysosome ([@B11]). CpG ODNs are classified into three main classes: A, B, and C. CpG ODNs have various immune functions according to their sequence ([@B12]). CpG ODN stimulates a strong innate immunity response, which may be inhibited by suppressive/inhibitory ODN (iODN) ([@B7], [@B13]). Several reports have described a protective effect for iODN. Interestingly, Shirota et al. reported that an iODN (A151) protects mice from endotoxin shock. In addition, A151 inhibited STAT1 and STAT4 phosphorylation and signaling cascade activated by IFN-β induced by LPS and IL-12. However, endotoxin shock worsened by treatment with Class B CpG ODN ([@B5]).

Various factors are associated with sepsis and the onset of endotoxin shock, as well as the induction of inflammatory cytokines. Platelet-activating factor (PAF) is a phospholipid that plays a significant role in inducing inflammation such as endotoxin shock and sepsis ([@B14]). PAF promotes platelet aggregation and activation and is involved in disseminated intravascular coagulation (DIC) and sepsis ([@B15]--[@B17]). Furthermore, PAF promotes the synthesis and release of immunological mediators such as TNF during inflammation ([@B18], [@B19]). Jacob et al. recently showed that PAF treatment induced acute lethality in mice ([@B20]). The circulating endogenous PAF level is controlled by PAF acetylhydrolase (PAF-AH), which is a phospholipase. In an LPS-induced lethal shock and cecal ligation and puncture (CLP) model, recombinant PAF-AH (rPAF-AH) improved the survival rate *via* suppressing inflammatory responses ([@B21]). PAF-AH and rPAF-AH were also demonstrated to improve the survival rate in a Phase II clinical study of patients with sepsis or multiple injuries ([@B22]). Therefore, PAF-AH is considered a therapeutic target for the treatment of sepsis and endotoxin shock. In this study, we examined the effect of a Class A CpG ODN 1585 (CpG-A~1585~) on coagulation and inflammatory responses to PAF-induced sepsis and LPS treatment. CpG-A~1585~ strongly induced PAF-AH, improved PAF-induced acute lethal shock and fibrin deposition, and rescued mice from LPS-induced endotoxin shock *via* inhibition of inflammatory responses. These results provide a new strategy against sepsis using Class A CpG ODN.

Results {#S2}
=======

CpG-A~1585~ Strongly Induces PAF-AH *via* TLR9 {#S2-1}
----------------------------------------------

To investigate whether all classes of CpG ODN can induce PAF-AH, we examined the effect of CpG-A~1585~, -B~1826~, and -C~2395~ on induction of *paf-ah2* mRNA expression and PAF-AH activity in splenocytes *in vitro*. Interestingly, we found that only CpG-A~1585~ significantly induced *paf-ah2* mRNA expression compared to other ODNs (*p* \< 0.01) (Figure [1](#F1){ref-type="fig"}A; Figure [S1](#SM1){ref-type="supplementary-material"}A in Supplementary Material). Inhibitory ODN H154 (iODN~H154~), a TLR9-specific antagonist, significantly suppressed CpG-A~1585~-induced *paf-ah2* mRNA expression and PAF-AH activity (*p* \< 0.01) (Figure [1](#F1){ref-type="fig"}B). Since CpG-A~1585~ containing unmethylated CpG dinucleotides triggers the vertebrate immune response through TLR9 activation ([@B23], [@B24]), we examined whether a CpG motif in CpG-A~1585~ would affect CpG-A~1585~-induced *paf-ah2* mRNA expression using non-CpG ODN of CpG-A~1585~ (non-CpG-A~1585~). We found that Crt~1612~ and non-CpG-A~1585~ did not induce *paf-ah2* mRNA expression (Figure [1](#F1){ref-type="fig"}C). In addition, CpG-A~1585~ showed stronger PAF-AH activity compared with control (Ctr~1612~), whereas pretreatment of iODN~H154~ and non-CpG-A~1585~ showed insignificant PAF-AH activity compared with Ctr~1612~ (Figure [1](#F1){ref-type="fig"}D). Similar results were observed in peritoneal macrophages (Figures [1](#F1){ref-type="fig"}E,F). CpG ODNs, especially CpG-A, are known as IFN-α inducers ([@B12]). To investigate whether IFN-α is involved in induction of *paf-ah2* mRNA expression, we examined the response of polyinosinic-polycytidylic acid (poly(I:C)) as an IFN-α inducer and recombinant mouse IFN-α (rmIFN-α) on induction of *paf-ah2* mRNA expression. Poly (I:C) and rmIFN-α did not induce *paf-ah2* mRNA expression (Figures [S1](#SM1){ref-type="supplementary-material"}B,C in Supplementary Material). Taken together, these data suggest that only CpG-A~1585~ strongly induces PAF-AH *via* TLR9 but not IFN-α, and its production is derived from macrophages.

![Effect of CpG oligodeoxynucleotide (ODN) on platelet-activating factor acetylhydrolase (PAF-AH) gene and enzymatic activity. Splenocytes or peritoneal macrophages were incubated with 3 µM CpG ODN, 3 µM CpG ODN 3 h after iODN~H154~ treatment, or non-CpG-A~1585~. After 24-h CpG ODN stimulation, the cells or supernatant were collected and used for PAF-AH expression or activity determination by quantitative PCR or PAF-AH assay kit, respectively. *Paf-ah2* mRNA expression by **(A)** CpG-A~1585~, CpG-B~1826~, and CpG-C~2395~; **(B)** iODN~H154~ inhibition; **(C)** non-CpG-A~1585~; and **(D)** PAF-AH activity in splenocytes. **(E)** *paf-ah2* mRNA expression and **(F)** PAF-AH activity in peritoneal macrophages. Data are presented as the mean ± SD. \*\**p* \< 0.01, significant differences vs. phosphate-buffered saline and/or Ctr~1612~. Values with different letters (i.e., a, b, c, and d) represent significant differences (*p* \< 0.05).](fimmu-08-01049-g001){#F1}

CpG-A~1585~ Protects Mice from PAF-Induced Lethal Shock {#S2-2}
-------------------------------------------------------

It has been reported that PAF administration alone induces sudden death in mice ([@B20]). Moreover, PAF is known to be involved in DIC as a symptom of sepsis ([@B17], [@B25]). Therefore, we examined the ability of CpG-A~1585~ to protect mice from PAF-induced lethal shock and sudden death. We administered 50, 100, and 300 µg CpG-A~1585~ intraperitoneally (i.p.) 1, 3, and 5 days before PAF challenge (Figure [2](#F2){ref-type="fig"}A). CpG-A~1585~ treatment at the highest dose (300 µg) significantly improved 20-min mortality in all mice compared with those in the PAF group (*p* \< 0.0001), whereas 50 and 100 µg CpG-A~1585~ treatment did not advance mortality (Figure [2](#F2){ref-type="fig"}B).

![Protective effect of CpG-A~1585~ on platelet-activating factor (PAF)-induced lethal shock. **(A)** Experimental schedule to examine the effect of CpG-A~1585~ on PAF-induced sudden death. After 1 week of rearing, ICR mice were injected with 50, 100, or 300 µg CpG-A~1585~ with or without methyl arachidonyl fluorophosphonate (MAFP) (1 mg/kg) 1, 3, and 5 days before receiving 50 µg PAF containing 0.1% human serum albumin. **(B)** Survival was monitored for 60 min. *N* = 8 mice per group.](fimmu-08-01049-g002){#F2}

We next applied methyl arachidonyl fluorophosphonate (MAFP) treatment, a PAF-AH inhibitor, to determine whether the effect of CpG-A~1585~ is dependent on PAF-AH. It has been shown that monocytes and thrombin-stimulated human coronary artery endothelial cells accumulated PAF following decreased PAF-AH when treated with MAFP *in vitro* ([@B26], [@B27]), and LPS-induced plasma PAF-AH activity was inhibited by MAFP *in vivo* ([@B28]). As expected, MAFP reduced the survival from 100 to 40% in the 300 µg CpG-A~1585~ group (Figure [2](#F2){ref-type="fig"}B). Taken together, CpG-A~1585~ protects mice from PAF-induced sudden death, and this effect is dependent on PAF-AH.

CpG-A~1585~ Alleviates PAF-Induced Blood Clots {#S2-3}
----------------------------------------------

As our studies demonstrated that CpG-A~1585~ was effective for PAF-induced lethal shock, we sought to clarify the mechanism by which CpG-A~1585~ protects mice from PAF-induced lethal shock. Severe congestion was confirmed in the PAF group compared with the non-treated (NT) group, which was improved by CpG-A~1585~ treatment (Figure [3](#F3){ref-type="fig"}A). It was reported that PAF promotes platelet aggregation ([@B15]). Therefore, we investigated platelet aggregation by measuring heart blood volume. Heart blood volume in the PAF group was significantly decreased compared with the NT group (*p* \< 0.01), whereas CpG-A~1585~ significantly improved heart blood volume (*p* \< 0.01) (Figure [3](#F3){ref-type="fig"}B). In hematoxylin-eosin (HE) and phosphotungstic acid hematoxylin (PTAH)-stained sections (Figures [3](#F3){ref-type="fig"}C,D), increased fibrin in a fibrin thrombus and an interlobular vein to renal corpuscle was observed in the PAF group compared with the NT group. In the CpG-A~1585~ + PAF group, fibrin thrombus size and fibrinosis were significantly decreased compared with the PAF group (Figure [3](#F3){ref-type="fig"}E). Serum analysis showed that PAF-AH activity was significantly increased in the CpG-A~1585~ + PAF group compared with the PAF group (*p* \< 0.01) (Figure [3](#F3){ref-type="fig"}F). These data suggest that CpG-A~1585~ ameliorates PAF-induced fibrin formation *via* PAF-AH activity.

![Mechanism of platelet-activating factor (PAF)-induced lethal shock ameliorated by CpG-A~1585~. ICR mice were injected with 300 µg CpG-A~1585~ for 1, 3, and 5 days before receiving 50 µg PAF containing 0.1% human serum albumin. Mice were then euthanized within 10 min after PAF injection. **(A)** Representative image of the abdominal cavity of (i) non-treated (NT), (ii) PAF-treated, and (iii) CpG-A~1585~ + PAF-treated mice. **(B)** Heart blood volume. **(C)** Hematoxylin-eosin staining, which shows polycythemia and morphological changes in the kidney. (i) NT, (ii) PAF-treated, and (iii) CpG-A~1585~ + PAF-treated mice. Scale bar = 100 μm. (iv) NT, (v) PAF-treated, and (vi) CpG-A~1585~ + PAF-treated mice. Scale bar = 20 μm. Fibrin thrombus is stained dark red. **(D)** Phosphotungstic acid hematoxylin staining, which shows fibrin accumulation in the kidney. (i) NT, (ii) PAF-treated, and (iii) CpG-A~1585~ + PAF-treated mice. Scale bar = 100 μm. (iv) NT, (v) PAF-treated, and (vi) CpG-A~1585~ + PAF-treated mice. Scale bar = 20 μm. Fibrin is stained dark blue. FB, fibrin; RBC, red blood cell; RC, renal corpuscle; RT, renal tubule; VI, interlobar veins. **(E)** The area of fibrin accumulation was determined by Image Processing Software, and the results are presented as the mean ± SE (*N* = 9 samples per group). **(F)** Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in mice. *N* = 8 mice per group. Data are presented as the mean ± SE. Values with different letters (i.e., a, b, and c) represent significant differences (*p* \< 0.05).](fimmu-08-01049-g003){#F3}

CpG-A~1585~ Inhibits TNF-α {#S2-4}
--------------------------

Platelet-activating factor has been shown to play a fundamental role in the regulation of TNF secretion *in vitro* ([@B29]). Here, we examined the effects of CpG-A~1585~-induced PAF-AH on inflammatory responses generated by LPS stimulation. CpG-A~1585~ reduced LPS-induced TNF-α mRNA and protein expression levels (Figures [4](#F4){ref-type="fig"}A,B). These data suggest that CpG-A~1585~-induced PAF-AH can regulate inflammatory responses.

![Suppressive effects of CpG-A~1585~ on lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production. Splenocytes were first incubated with 3 µM CpG-A~1585~ and then incubated with LPS (10 ng/ml). After LPS stimulation, the cells or supernatant was collected and used to evaluate *tnf-*α mRNA expression or TNF-α protein level by quantitative PCR or enzyme-linked immunosorbent assay, respectively. **(A)** *tnf-*α mRNA expression and **(B)** TNF-α protein level in splenocytes. Data are presented as the mean ± SE. Values with different letters (i.e., a, b, and c) represent significant differences (*p* \< 0.05).](fimmu-08-01049-g004){#F4}

CpG-A~1585~ Protects Mice from LPS-Induced Endotoxin Shock {#S2-5}
----------------------------------------------------------

In previous studies on the use of CpG ODNs for endotoxin shock and sepsis, Class B CpG ODN was confirmed to reduce survival in an experimental murine model of endotoxin shock or prevent sepsis-induced mortality ([@B5], [@B30], [@B31]). However, the effect of CpG-A ODN on endotoxin shock remains unclear. In addition, LPS is involved in PAF synthesis and PAF-induced diseases *in vitro* and *in vivo* ([@B32], [@B33]). Therefore, to determine whether CpG-A ODN could protect mice from LPS-induced endotoxin shock, mice were administered CpG-A~1585~ *via* i.p. injection 3 h before LPS challenge (Figure [5](#F5){ref-type="fig"}A). CpG-A~1585~ significantly improved 24-h mortality in the CpG-A~1585~ + LPS group compared with the LPS group (*p* \< 0.0005) (Figure [5](#F5){ref-type="fig"}B). In addition, CpG-A~1585~ treatment improved hypothermia (Figure [5](#F5){ref-type="fig"}C). However, MAFP worsened hypothermia (Figure [S2](#SM2){ref-type="supplementary-material"} in Supplementary Material). In addition, PAF-AH activity was significantly increased in the CpG-A~1585~ group compared with the control group at 12 h after LPS challenge (at 15 h after CpG-A~1585~ treatment) (*p* = 0.0199). IL-6 and TNF-α expression levels were significantly inhibited in the CpG-A~1585~ group compared with the control group at 12 h after LPS challenge (*p* = 0.0001 and *p* = 0.0001, respectively) (Figures [5](#F5){ref-type="fig"}D--F). Particularly, TNF-α expression levels in mice pretreated with CpG-A~1585~ (45.4 ± 17.6 pg/ml) were significantly lower than those in mice that received LPS only (190 ± 53.6 pg/ml) (*p* \< 0.001). These results suggest that CpG-A~1585~ pretreatment effectively protects mice from LPS-induced endotoxin shock.

![Protective effect of CpG-A~1585~ on lipopolysaccharide (LPS)-induced endotoxin shock. **(A)** Experimental schedule to examine the effect of CpG-A~1585~ on LPS-induced endotoxin shock. BALB/c mice were intraperitoneally injected with 300 µg CpG-A~1585~ 3 h before challenge with 750 µg LPS. **(B)** Survival and **(C)** changes in body temperature were monitored for 24 h. **(D)** Kinetics of platelet-activating factor acetylhydrolase (PAF-AH) activity in serum collected from the tail vein after receiving 300 µg CpG-A~1585~ and 750 µg LPS. **(E)** Serum interleukin (IL)-6 and **(F)** tumor necrosis factor (TNF)-α levels in mice that received LPS with or without 300 µg CpG-A~1585~ 12 h after LPS challenge. *N* = 8 mice per group. Data are presented as the mean ± SE. \**p* \< 0.05 and \*\**p* \< 0.01, significant differences between the LPS and CpG-A~1585~ + LPS groups.](fimmu-08-01049-g005){#F5}

Discussion {#S3}
==========

In 2016, the definitions of sepsis and septic shock were revised. Sepsis complicated by organ dysfunction was termed *severe sepsis*, which could progress to septic shock, defined as "sepsis-induced hypotension persisting despite adequate fluid resuscitation" ([@B34]). Sepsis is characterized by an excessive cytokine response and blood clotting reaction and is significantly involved in tissue injury and mortality ([@B35]). Here, we suggest that CpG-A~1585~ resolves septic and endotoxin shock through an anti-inflammatory response and improvement of DIC (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} and [5](#F5){ref-type="fig"}).

We showed that CpG-A~1585~ improved PAF-induced acute lethality, which was abrogated by a PAF-AH inhibitor, MAFP (Figures [2](#F2){ref-type="fig"} and [6](#F6){ref-type="fig"}). Chen et al. showed that MAFP is a potent irreversible inhibitor of PAF-AH ([@B26]). In addition, Wu et al. also used MAFP as a specific inhibitor of PAF-AH and demonstrated that MAFP treatment inhibited plasma PAF-AH activity in an LPS-induced lung inflammation model. Further, Wu et al. mentioned that this finding strongly supported the involvement of PAF ([@B28]). In an experimental murine model of sepsis, acute lethal shock occurred by PAF-induced DIC. DIC is caused by pathological dysregulation of coagulation and fibrinolysis ([@B36]). The results of decreased heart blood volume and HE and PTAH staining demonstrated clear hallmarks of DIC (Figures [3](#F3){ref-type="fig"}B--D), particularly the presence of fibrin ([@B25]). CpG-A~1585~ treatment ameliorated blood loss and fibrin accumulation aggravated by PAF (Figures [3](#F3){ref-type="fig"}B--E) and significantly increased PAF-AH activity in serum (Figure [3](#F3){ref-type="fig"}F). In a previous study, the administration of a PAF antagonist improved DIC symptoms ([@B17]). This report suggests that PAF-inhibitors improve DIC. Namely, PAF-AH has the ability to improve DIC indirectly by generating lyso-PAF. Therefore, these results confirm that CpG-A~1585~ dissolves PAF *via* PAF-AH activation, improving PAF-induced sudden death in mice (Figure [6](#F6){ref-type="fig"}).

![Overview of sepsis prevention by CpG-A~1585~ priming. Leukocytes including macrophages, monocytes, eosinophils, neutrophils, and basophils produce platelet-activating factor (PAF), which plays a significant role in the pathogenesis of endotoxin shock and sepsis in response to invading pathogens. PAF is degraded into lyso-PAF by platelet-activating factor acetylhydrolase (PAF-AH), resulting in the deactivation of PAF. CpG-A~1585~ induces PAF-AH from splenocytes, especially macrophages, *via* a TLR9-dependent pathway. Although CpG-A~1585~ is a strong inducer of interferon (IFN)-α, CpG-A~1585~-induced IFN-α does not affect PAF-AH. CpG-A~1585~ inhibits PAF-induced blood clotting *via* induction of PAF-AH, and this effect is inhibited by a PAF-AH-specific inhibitor, methyl arachidonyl fluorophosphonate (MAFP).](fimmu-08-01049-g006){#F6}

There are several experimental murine models of sepsis: (a) LPS-induced endotoxin shock model; (b) endogenic protection barrier model, such as CLP and colon ascendens stent peritonitis (CASP); and (c) external cause-related bacterial administration model. We used the LPS-induced endotoxin shock model, which was shown to exhibit systemic inflammation similar to initial clinical features in sepsis ([@B37]), and demonstrated that CpG-A improved endotoxin shock in this model. CpG-B was previously demonstrated to improve survival through IL-17 in the CLP model and enhanced cardiac dysfunction in the CLP model ([@B30], [@B38]). CpG-B may also stimulate neutrophil accumulation and improve survival by promoting bacterial exclusion ([@B31]). In another study, rPAF-AH administration increased bacterial clearance and enhanced the ability of macrophages to engulf invading bacteria ([@B21]). In addition, CpG-A~1585~ strongly induces PAF-AH, which may be useful for protection against CLP- and CASP-induced bacterial infection. Therefore, prevention and treatment of sepsis and control of inflammatory responses are important.

Various inflammation-associated factors, including LPS, TNF-α, IL-1, nitric monoxide, PAF, Braun's lipoprotein (BLP), and high-mobility group box 1 protein, promote inflammation leading to sepsis ([@B39], [@B40]). It has been reported that anti-TNF antibody protects mice from LPS-induced lethal shock in a dose-dependent manner ([@B41]). Therefore, TNF-α control is a potential treatment strategy for sepsis and septic shock. In addition, an agonist of calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide type I receptor inhibited LPS-induced TNF-α and improved survival from endotoxin shock ([@B42], [@B43]). Our results supported these reports. In addition, BLP, a pro-inflammatory component of *Escherichia coli* membrane, stimulates endotoxemia similar to LPS *via* TLR2. It was also shown that PAF synthesis was induced by BLP ([@B40]). Taken together, CpG-A~1585~ may be effective for endotoxemia induced by both LPS and BLP.

In the present study, we further investigated CpG-A~1585~-induced PAF-AH using peritoneal macrophages and spleen cells (Figures [1](#F1){ref-type="fig"}D,F), as macrophages are known to secrete PAF-AH ([@B44], [@B45]). Moreover, several groups have reported TLR4/9 cross-tolerance ([@B5], [@B46], [@B47]), which is a strong anti-inflammatory LPS response induced by pretreatment with CpG-A~1585~ ([@B47]). Interestingly, our findings indicated that pretreatment with CpG-A~1585~ significantly increased PAF-AH in the early stage of TNF-α production in the septic/endotoxin shock model. In addition, we revealed that a PAF-AH inhibitor reduced survival in the PAF-induced acute lethal model. Hospitalized patients have a high risk of contracting septic shock because of weakened immune systems. In addition, sepsis is a disease that has low survival once contracted. CpG-A is an immunological enhancement molecule that is expected not only to prevent sepsis but also to enhance immune responses. Our findings confirm the importance of PAF and its function in septic/endotoxin shock.

Materials and Methods {#S4}
=====================

ODNs and Reagents {#S4-1}
-----------------

Endotoxin-free desalted PS-ODNs were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA, USA) or Gene Design, Inc. (Osaka, Japan). PS-ODNs were reconstituted in phosphate-buffered saline (PBS) and passed through a 0.22-µm pore microfilter (Nihon Millipore K.K., Tokyo, Japan). ODN sequences are shown in Table [1](#T1){ref-type="table"}: CpG-A~1585~ ([@B48]), CpG-B~1826~ ([@B49]), CpG-C~2395~ ([@B50]), Ctr~1612~ ([@B51]), non-CpG-A~1585~, and iODN~H154~ ([@B13]). LPS from *Escherichia coli* 0127:B8 was purchased from Sigma-Aldrich (St. Louis, MO, USA). MAFP and PAF C-16 were purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). Poly(I:C) was purchased from InvivoGen (San Diego, CA, USA). rmIFN-α was purchased from BioLegend (San Diego, CA, USA).

###### 

ODN sequences.

  Name              Sequence 5′--3′                                                     Reference
  ----------------- ------------------------------------------------------------------- ------------
  CpG-A~1585~       G\*GGGTCAACGTTGAG\*G\*G\*G\*G\*G                                    ([@B48])
  non-CpG-A~1585~   G\*GGGTCAAGCTTGAG\*G\*G\*G\*G\*G                                    This study
  CpG-B~1826~       T\*C\*C\*A\*T\*G\*A\*C\*G\*T\*T\*C\*C\*T\*G\*A\*C\*G\*T\*T          ([@B49])
  CpG-C~2395~       T\*C\*G\*T\*C\*G\*T\*T\*T\*T\*C\*G\*G\*C\*G\*C\*G\*C\* G\*C\*C\*G   ([@B50])
  Ctr~1612~         G\*C\*T\*A\*G\*A\*G\*C\*T\*T\*A\*G\*G\*C\*T                         ([@B51])
  iODN~H154~        C\*C\*T\*C\*A\*A\*G\*C\*T\*T\*G\*A\*G\*G\*G\*G                      ([@B13])

*\*Phosphorothioate bond*.

Mice {#S4-2}
----

Female BALB/c and male ICR (Swiss albino) mice (6 weeks of age) were purchased from Japan SLC (Shizuoka, Japan), housed under temperature- and light-controlled conditions, and fed a standard diet (MF, Oriental Yeast Co. Ltd., Tokyo, Japan) and sterile water *ad libitum*. Mice were used for experiments after preliminary housing for 1 week.

Cells and Cell Culture {#S4-3}
----------------------

Splenocytes from female BALB/c mice (8 weeks of age) were prepared using standard methods. Cells were seeded onto 24-well plates (Nalge Nunc International K.K., Tokyo, Japan) at a final concentration of 1 × 10^6^ cells/well in complete RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% fetal calf serum (Sigma-Aldrich), 100 U/ml of penicillin, 100 mg/ml of streptomycin, 25 mM HEPES, 1.0 mM sodium pyruvate, non-essential amino acids, and 0.0035% 2-ME. Cells were then treated with 0.01--10 µM CpG ODN, 0.01--10 µg poly(I:C), or 0.01--1 ng rmIFN-α for 24 h (total 1 ml/well) (Figure [1](#F1){ref-type="fig"}; Figure [S1](#SM1){ref-type="supplementary-material"} in Supplementary Material). After treatment, the cells and supernatant were collected for real-time quantitative PCR (qPCR) and PAF-AH enzymatic activity analysis, respectively. Cells were treated with 3 µM CpG-A~1585~ for 24 h, followed by stimulation with 10 ng/ml LPS for 6 h for qPCR analysis or for 24 h for enzyme-linked immunosorbent assay (ELISA) (Figure [4](#F4){ref-type="fig"}). Peritoneal macrophages were collected from mercy-killed female BALB/c mice (8 weeks of age) by peritoneal lavage with 5 ml of cold PBS, centrifuged at 1,500 rpm for 5 min and resuspended in medium. Murine peritoneal macrophages were then preincubated and adhered to dishes in medium for 24 h before exposure to CpG ODNs. Cells were seeded onto 24-well plates at a final concentration of 1 × 10^5^ cells/well and then treated with 3 µM CpG ODN for 24 h (total 1 ml/well) for qPCR analysis and PAF-AH enzymatic activity analysis (total 1 ml/well).

PAF-Induced Lethal Shock Model {#S4-4}
------------------------------

A schematic schedule of the experimental procedure is shown in Figure [2](#F2){ref-type="fig"}A. To determine the effect of PAF on the survival of ICR mice, we divided the animals (6 weeks of age) into the following three groups: PAF group, CpG-A~1585~ + PAF group, and CpG-A~1585~ + MAFP + PAF group (*N* = 8 mice per group). ICR mice were i.p. injected with 50, 100, or 300 µg CpG-A~1585~ 1, 3, and 5 days before PAF challenge. MAFP (1 mg/kg) was i.p. injected 20 min before CpG-A~1585~ injection. A stock solution of PAF was made in methanol, and the required aliquot was dried under a stream of nitrogen. PAF was then reconstituted in 0.5 ml PBS containing 0.1% human serum albumin (Wako Pure Chemical Industries, Ltd., Osaka, Japan) before use and administered i.p. into Swiss albino mice. After each treatment, animals were monitored for up to 60 min for survival.

LPS-Induced Endotoxin Shock Model {#S4-5}
---------------------------------

A schematic schedule of the experimental procedure is shown in Figure [5](#F5){ref-type="fig"}A. BALB/c mice (7 weeks of age) were divided as follows: LPS group vs. CpG-A~1585~ + LPS group (Figure [5](#F5){ref-type="fig"}) and CpG-A~1585~ + LPS group vs. CpG-A~1585~/MAFP (5 mg/kg) + LPS group (Figure [S2](#SM2){ref-type="supplementary-material"} in Supplementary Material) (*N* = 8 mice per group). BALB/c mice were i.p. injected with 300 µg CpG-A~1585~ 3 h before LPS challenge. Mice receiving MAFP (5 mg/kg) were i.p. injected 20 min before CpG-A~1585~ injection. The LPS-induced endotoxin shock model was established by i.p. injection of LPS (750 µg; Sigma-Aldrich). Survival was recorded at 0, 3, 6, 9, 12, 15, 18, 21, and 24 h. Body temperature (degree Celsius) was measured at 3-h intervals using an NTC thermistor (Tateyama Kagaku Industry Co., Ltd., Toyama, Japan).

Blood Collection from Heart {#S4-6}
---------------------------

Mice were euthanized by cervical dislocation 10 min after PAF injection. The maximum amount of blood was collected from the heart using a 10-ml syringe and 18 G needle within 5 min of death. The blood was weighed by ELECTRONIC BALANCE IBA-200 (AS ONE Corporation, Osaka, Japan). The volume (in milliliters) was calculated using the specific gravity (1.035) of mouse blood. The progression of blood clotting was evaluated by the quantity of collected blood.

Histopathology {#S4-7}
--------------

The kidney, liver (quadrate lobule), and spleen were fixed with 10% formalin neutral buffer solution (Wako Pure Chemical Industries, Ltd.), embedded in paraffin, sliced, and stained with HE and PTAH. Slicing and staining of embedded blocks were performed by Biopathology Institute (Oita, Japan). Histological pathology was evaluated under light microscopy. The area of fibrin accumulation was determined by Image Processing Software (Media Cybernetics Inc., Bethesda, MD, USA) and collected from three mice per group at adjacent axial locations.

qPCR Analysis {#S4-8}
-------------

Total RNA from the cells stimulated with CpG ODN and LPS was isolated using NucleoSpin^®^ RNA (TaKaRa Bio Inc., Tokyo, Japan). cDNA was prepared by reverse transcription from 1 µg of total RNA per sample using PrimeScript^®^ RT Master Mix (TaKaRa Bio Inc.). Equal volumes of cDNA were used for quantification of various cytokine cDNAs *via* qPCR using the Thermal Cycler Dice^®^ Real Time system (TaKaRa Bio, Inc.). qPCR analyses were performed with SYBR Premix Ex Taq (TaKaRa Bio, Inc.) using specific primers. Primers for β-actin, PAF-AH2, and TNF-α were purchased from TaKaRa Bio, Inc. For cross-sample comparison of results obtained following various treatments, cytokine mRNA levels were first normalized to those of β-actin mRNA. Data are shown as the mean ± SD of one representative experiment of three independent experiments with similar results.

Enzyme-Linked Immunosorbent Assay {#S4-9}
---------------------------------

TNF-α level in sera or cell culture supernatants was quantified using a commercially available ELISA kit (TNF-α, eBioscience Inc., San Diego, CA, USA) according to the manufacturer's instructions.

PAF-AH Activity Assay {#S4-10}
---------------------

Platelet-activating factor acetylhydrolase activity in supernatant or sera was measured using the PAF-AH assay kit (Cayman Chemical Co.) ([@B28]). Briefly, 10 µl sample and 10 µl 5,5′-dithiobis (2-nitrobenzoic acid) were added to wells of a 96-well plate. The reactions were initiated by adding 200 µl substrate solution (2-thio-PAF). The absorbance at 405 nm was read every minute using a plate reader (iMark™ Microplate Reader, Bio-Rad, Hercules, CA, USA).

Statistical Analysis {#S4-11}
--------------------

Statistical analyses were performed using a statistical software package ([ystat2004.xls](ystat2004.xls), Igaku Tosho Shuppan, Tokyo, Japan) or GraphPad Prism7 (GraphPad Software, Inc., La Jolla, CA, USA). All data were analyzed by one-way analysis of variance with the *post hoc* Student--Newman--Keuls test, except for survival analyses, *in vitro* qPCR analysis, PAF-AH activity assay, and all data from the LPS-induced endotoxin shock model. Survival analyses were performed using the log-rank test. *In vitro* qPCR analysis, PAF-AH activity assay, and all data from the LPS-induced endotoxin shock model were analyzed using Student's *t*-test and the Dunnett test. Differences were considered significant at *p* \< 0.05. Values for *in vitro* data are expressed as the mean ± SD. Other values are expressed as the mean ± SE.
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###### 

Effect of CpG-A~1585~, CpG-B~1826~, CpG-C~2395~, and interferon (IFN)-α dose on platelet-activating factor acetylhydrolase (PAF-AH) mRNA expression. Splenocytes were incubated with 0.01--10 µM CpG oligodeoxynucleotide (ODN), 0.01--10 µg/ml poly(I:C), or 0.01--1 ng/ml rmIFN-α. After 24-h CpG ODN stimulation, the cells were collected and used for PAF-AH expression determination by quantitative PCR. *Paf-ah2* mRNA expression by **(A)** CpG-A~1585~, -B~1826~, and -C~2395~ dose, **(B)** poly(I:C) dose, and **(C)** rmIFN-α dose in splenocytes. Data are presented as the mean ± SD. \*\**p* \< 0.01, significant differences compared to phosphate-buffered saline (PBS).

###### 

Click here for additional data file.

###### 

Effect of a platelet-activating factor acetylhydrolase inhibitor on amelioration of lipopolysaccharide (LPS)-induced endotoxin shock by CpG-A~1585~. **(A)** Experimental schedule to examine the effect of methyl arachidonyl fluorophosphonate (MAFP) on LPS-induced endotoxin shock ameliorated by CpG-A~1585~. BALB/c mice were intraperitoneally injected with 5 mg/kg MAFP for 20 min before receiving 300 µg CpG-A~1585~. After 3 h, the mice were challenged with 750 µg LPS. **(B)** Changes in body temperature within 24 h. *N* = 8 mice per group. Data are presented as the mean ± SE.

###### 

Click here for additional data file.
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